High Content Screening
Chairs: | Enrico Schmidt, Novartis Pharma AG (Basel, CH) |
| Neil Carragher, Edinburgh Cancer Research Centre (Edinburgh, UK) |
Session Summary:
Sub-cellular imaging using automated microscopy in combination with automated image analysis is widely known under the name of high-content screening (HCS). HCS was first introduced over a decade ago as one of the promising new technologies intended to address the bottleneck of secondary assays in the development of new drugs. Since then the application has rapidly expanded throughout the entire drug discovery process, from target identification and validation through lead optimization to detailed investigation of mode of action. An area where HCS is emerging is the high-throughput screening of small molecules for lead finding and the incorporation of more complex 3-dimensional and live cell assays into screening cascades.
The session will cover new advances in technology and applications in the HCS area as well as case studies from academia and industry.